# Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

> **NCT00055874** · PHASE3 · COMPLETED · sponsor: **Heidelberg University** · enrollment: 1551 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** cytarabine
- **DRUG:** hydroxyurea
- **DRUG:** imatinib mesylate
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** autologous bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00055874
- **Lead sponsor:** Heidelberg University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2012-03-31
- **Final completion:** 2017-03-31
- **Target enrollment:** 1551 (ACTUAL)
- **Last updated:** 2018-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055874, "Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00055874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*